These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 22160026)
21. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Warkentin TE; Greinacher A Chest; 2004 Sep; 126(3 Suppl):311S-337S. PubMed ID: 15383477 [TBL] [Abstract][Full Text] [Related]
22. Heparin-induced thrombocytopenia. Warkentin TE Hematol Oncol Clin North Am; 2007 Aug; 21(4):589-607, v. PubMed ID: 17666280 [TBL] [Abstract][Full Text] [Related]
23. Current management of heparin-induced thrombocytopenia. Cosmi B Expert Rev Hematol; 2015 Dec; 8(6):837-49. PubMed ID: 26368591 [TBL] [Abstract][Full Text] [Related]
24. Heparin-induced thrombocytopenia: diagnosis and management. Liebman HA Vascular; 2008; 16 Suppl 1():S71-6. PubMed ID: 18544310 [TBL] [Abstract][Full Text] [Related]
25. A diagnosis of heparin-induced thrombocytopenia with combined clinical and laboratory methods in cardiothoracic surgical intensive care unit patients. Demma LJ; Winkler AM; Levy JH Anesth Analg; 2011 Oct; 113(4):697-702. PubMed ID: 21788317 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Fondaparinux in Patients With Suspected Heparin-Induced Thrombocytopenia. Snodgrass MN; Shields J; Rai H Clin Appl Thromb Hemost; 2016 Nov; 22(8):712-717. PubMed ID: 27179015 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of heparin-induced thrombocytopenia (HIT) laboratory testing and the 4Ts scoring system in the intensive care unit. Pierce W; Mazur J; Greenberg C; Mueller J; Foster J; Lazarchick J Ann Clin Lab Sci; 2013; 43(4):429-35. PubMed ID: 24247801 [TBL] [Abstract][Full Text] [Related]
29. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Greinacher A; Gopinadhan M; Günther JU; Omer-Adam MA; Strobel U; Warkentin TE; Papastavrou G; Weitschies W; Helm CA Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2386-93. PubMed ID: 16873726 [TBL] [Abstract][Full Text] [Related]
30. HIT paradigms and paradoxes. Warkentin TE J Thromb Haemost; 2011 Jul; 9 Suppl 1():105-17. PubMed ID: 21781246 [TBL] [Abstract][Full Text] [Related]
31. Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT)--findings from the GerHIT multi-centre registry study. Schindewolf M; Steindl J; Beyer-Westendorf J; Schellong S; Dohmen PM; Brachmann J; Madlener K; Pötzsch B; Klamroth R; Hankowitz J; Banik N; Eberle S; Kropff S; Müller MM; Lindhoff-Last E Thromb Res; 2014 Jul; 134(1):29-35. PubMed ID: 24703295 [TBL] [Abstract][Full Text] [Related]
36. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Warkentin TE; Greinacher A; Koster A; Lincoff AM Chest; 2008 Jun; 133(6 Suppl):340S-380S. PubMed ID: 18574270 [TBL] [Abstract][Full Text] [Related]
37. Effectiveness of a new immunoassay for the diagnosis of heparin-induced thrombocytopenia and improved specificity when detecting IgG antibodies. Pouplard C; Leroux D; Regina S; Rollin J; Gruel Y Thromb Haemost; 2010 Jan; 103(1):145-50. PubMed ID: 20062918 [TBL] [Abstract][Full Text] [Related]
38. High sensitivity and specificity of a new functional flow cytometry assay for clinically significant heparin-induced thrombocytopenia antibodies. Garritsen HS; Probst-Kepper M; Legath N; Eberl W; Samaniego S; Woudenberg J; Schuitemaker JH; Kroll H; Gurney DA; Moore GW; Zehnder JL Int J Lab Hematol; 2014 Apr; 36(2):135-43. PubMed ID: 23981347 [TBL] [Abstract][Full Text] [Related]
39. Agents for the treatment of heparin-induced thrombocytopenia. Warkentin TE Hematol Oncol Clin North Am; 2010 Aug; 24(4):755-75, ix. PubMed ID: 20659659 [TBL] [Abstract][Full Text] [Related]
40. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]